Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

Journal of Clinical Pharmacology - Tập 49 Số 6 - Trang 643-649 - 2009
Amy K. Katz1, Chandrasekhar Udata, Elyssa Ott, Lisa Hickey, Michael E. Burczynski, Peter H. Burghart, O. Vesterqvist, Meng Xu
1500 Arcola Road, A-3, Collegeville, PA 19426, USA. [email protected]

Tóm tắt

Liver X‐receptor (LXR) agonists have been postulated to enhance reverse cholesterol transport (RCT), a process believed to shuttle cholesterol from the periphery back to the liver. Enhancing RCT via the upregulation of cholesterol transporters such as the adenosine triphosphate—binding cassettes ABCA1 and ABCG1 could therefore inhibit the progression of atherosclerosis. LXR‐623 is a synthetic ligand for LXRs α and β that has shown promise in animal models of atherosclerosis. The authors present results from a single ascending‐dose study of the safety, pharmacokinetics, and pharmacodynamics of LXR‐623 in healthy participants. LXR‐623 was absorbed rapidly with peak concentrations (Cmax) achieved at approximately 2 hours. The Cmax and area under the concentration‐time curve increased in a dose‐proportional manner. The mean terminal disposition half‐life was between 41 and 43 hours independently of dose. LXR activation resulted in a dose‐dependent increase in ABCA1 and ABCG1 expression. The effect of LXR‐623 concentration on ABCA1 and ABCG1 expression was further characterized via a population pharmacokinetic‐pharmacodynamic analysis, yielding EC50 estimates of 526 ng/mL and 729 ng/mL, respectively. Central nervous system—related adverse events were observed at the 2 top doses tested. The pharmacodynamic effects described here are the first demonstration of “target engagement” by an LXR agonist in humans.

Từ khóa


Tài liệu tham khảo

10.1126/science.289.5484.1524

10.1101/gad.850400

10.1074/jbc.M003337200

10.1073/pnas.98.2.507

10.1172/JCI8573

10.1006/bbrc.2000.3243

10.1073/pnas.200367697

10.1074/jbc.275.19.14700

10.1126/science.290.5497.1771

10.1038/11914

10.1038/11905

10.1194/jlr.M500116-JLR200

10.1074/jbc.M109927200

10.1038/11921

10.1515/CCLM.2005.085

10.2174/156720507780362227

10.1016/j.mcn.2007.01.011

Nambi P, 2007, LXR‐623, a novel liver X receptor modulator, displays neutral lipid effects in cholesteryl ester transfer protein‐expressing species and inhibits atherosclerotic lesion progression in low density lipoprotein receptor knockout mice, Circulation, 116

Quinet E, 2007, A novel LXR ligand reduces LDL cholesterol in monkey, Circulation, 116

10.1186/1479-5876-6-59

10.1002/cpt1979253358

10.2174/156720507780362173

10.1074/jbc.M411420200

10.1074/jbc.M209085200

10.1111/j.1471-4159.2006.03925.x

10.1385/JMN:23:3:219

10.1074/jbc.M300760200

10.1210/mend.16.6.0835

10.1016/j.neurobiolaging.2005.08.010

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 49 Số 6

643-649

Thông tin tác giả